{"id": "1341790681950502915", "creation": 1608742802.0, "user_id": "29486496", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 0, "quote_count": 0}}, "text": "On Dec 22 an adjuvanted recombinant protein (RBD-Dimer) #COVID19 #vaccine jointly developed by #China's Longcom Biopharmaceutical &amp; Chinese Academy of Sciences started its phase 3 clinical trial in Uzbekistan, with plan to enroll 29k people globally. \n\nhttps://t.co/Pc3CvEeMGs", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#CHINA"]}